AlphAIalphai — Financial news for AI agents
aol.comAUG 43 min read$TGTX

TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics Inc. (TGTX) reported Q2 net income of $7.8 million, or 5 cents per share, below Wall Street expectations of 41 cents per share, according to Zacks. Revenue was $240.3 million, above the $230.9 million forecast. The company expects full-year revenue of $950 million.

Original reporting
aol.com
Published Aug 4, 2026, 12:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 5:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
TG Therapeutics: Q2 Earnings Snapshot — source image
Source · aol.com
Decision brief

The 30-second read

$TGTXNeutralMed
01

Why it matters

Traders can reassess near-term expectations based on the EPS miss versus revenue beat and the stated FY revenue target of $950M.

02

Market read

A straightforward earnings and guidance update with a clear EPS miss and a revenue beat, likely prompting estimate revisions.

03

What to watch

The article does not include cash flow, segment performance, or pipeline updates, which could be the real drivers behind any sustained repricing.

Relevance 7/10Novelty 6/10Timing: reported Q2 results and full-year revenue guidance on Monday

Background

AP earnings snapshot for TG Therapeutics’ second quarter, including EPS, revenue, and full-year revenue guidance.

Company-level read

Ticker impact

$TGTXNeutralMedium confidence
Context

TG Therapeutics reported Q2 net income of $7.8M, or $0.05/share, below the $0.41/share analyst average, and guided FY revenue to $950M.

Expected impact

Near-term volatility likely, with focus on the EPS miss versus the revenue beat and the $950M FY revenue outlook.

Evidence & confidence

The article provides concrete Q2 EPS and revenue figures plus a full-year revenue forecast, which can drive revisions and positioning even without additional qualitative catalysts.

Market effects

Sector

Adds another datapoint on biopharma earnings quality, where revenue beats may not offset EPS misses.

Regional

No specific regional spillover beyond a US-listed biotech earnings print.

Global

Limited, as the article contains company-specific results without broader macro or regulatory developments.

Counterpoint

What could challenge this read

Investors may discount the EPS miss if revenue strength and the $950M FY revenue expectation signal demand resilience.

Key entities

  • company
    TG Therapeutics Inc.

    Reported Q2 net income of $7.8M ($0.05/share), revenue of $240.3M, and guided full-year revenue to $950M.

  • analyst_source
    Zacks Investment Research

    Provided the consensus EPS and revenue expectations cited in the article.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 5
$TGTXMed

TG Therapeutics, Inc. Q2 2026 Earnings Call Summary

TG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.

yahoo.com5 min
AUG 3
$TGTXMed

TG Therapeutics Inc. Reports Fall In Q2 Bottom Line

TG Therapeutics (TGTX.OB) reported Q2 results. Net income fell to $7.78 million, or $0.05 per share, from $28.19 million, or $0.17 per share, a year earlier. Revenue rose 70.3% to $240.33 million from $141.15 million. Full-year revenue guidance is $890 million to $905 million.

rttnews.com2 min
AUG 3
$TGTXMedAI 8/10

Why is TG Therapeutics stock sliding today?

Investing.com reports TG Therapeutics (TGTX) shares fell about 4.7% pre-open to $49.60 after its Q2 2026 results. The company said revenue was $240.3M versus ~$228.85M expected, and it raised FY2026 global revenue to about $950M and Briumvi U.S. net product revenue guidance to $890M-$905M. Despite beats, the market had priced in strong growth.

investing.com3 min
AUG 3
$TGTXHigh

TG THERAPEUTICS, INC. (TGTX): Results of Operations and Financial Condition

TG THERAPEUTICS, INC. (TGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_997107.htm EXHIBIT 99.1 ex_997107.htm Exhibit 99.1 TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue o

SEC EDGAR 8-K6 min
JUL 16
$NVSMed

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

Australia’s health minister Mark Butler said an expert panel will keep MS drugs Ocrevus, Kesimpta and Lemtrada on the PBS, maintaining taxpayer subsidies after manufacturers sought higher payments. The PBAC also ordered a rapid review of MS drug use to be completed by year end. The article cites possible price cuts tied to US “Most Favoured Nation” policy and PBS reference pricing.

theguardian.com7 min